{
    "id": "dbpedia_1750_3",
    "rank": 4,
    "data": {
        "url": "https://www.dana-farber.org/find-a-doctor/paul-l-nguyen",
        "read_more_link": "",
        "language": "en",
        "title": "Paul L. Nguyen, MD, MBA - Dana-Farber Cancer Institute",
        "top_image": "https://www.dana-farber.org/sites/default/files/favicon.ico",
        "meta_img": "https://www.dana-farber.org/sites/default/files/favicon.ico",
        "images": [
            "https://dfci.widen.net/content/110ca04f-81c4-49f9-8e22-28a6ce5b3d0d/web/DFCI%20Logo%20Lens%20Color-rgb.svg",
            "https://dfci.widen.net/content/ri9n147djk/web/nurse-practitioner-and-patient556x381.jpg?crop=yes&k=c&w=600&h=368&itok=d4Yi5_AR",
            "https://dfci.widen.net/content/htfmtrxnyd/web/healthy-raw-vegetables556x381.jpg?crop=yes&k=c&w=600&h=368&itok=IcqGg6fP",
            "https://dfci.widen.net/content/oxtykuypie/web/Maria-Luisa-Guerrera-Bing%20Center-Waldenstr%C3%B6ms-Macroglobulinemia?crop=yes&k=c&w=600&h=368&itok=OQoc7eAo",
            "https://dfci.widen.net/content/f8qik7fbpb/web/cpop-team?crop=yes&k=c&w=600&h=368&itok=POlIPQUu",
            "https://dfci.widen.net/content/gswououikf/web/hych-radio-telethon-600x368.jpg?crop=yes&k=c&w=600&h=368&itok=JhBnN0Ia",
            "https://dfci.widen.net/content/megjz0gzpk/web/kimmie-ng-and-patient556x381.jpg?crop=yes&k=c&w=600&h=368&itok=patrnNAo",
            "https://dfci.widen.net/content/110ca04f-81c4-49f9-8e22-28a6ce5b3d0d/web/DFCI%20Logo%20Lens%20Color-rgb.svg",
            "https://www.dana-farber.org/sites/default/files/providers/29761.jpg",
            "https://www.dana-farber.org/sites/default/files/providers/top-doctor-award.png",
            "https://www.dana-farber.org/sites/default/files/styles/location_listing_image_desktop/public/providers/location_avtar.png?itok=ftkJEpXC",
            "https://www.dana-farber.org/sites/default/files/styles/location_listing_image_desktop/public/providers/location_avtar.png?itok=ftkJEpXC",
            "https://www.dana-farber.org/sites/default/files/styles/card_392x275_/public/uploadedimages/expressreleases/Prostate%2520Cancer%2520Cells%2520from%2520DF%2520copy%281%29.jpg?itok=vR8Hr_fN 1x",
            "https://dfci.widen.net/content/b77baa3d-5752-4cb4-b5fa-a7a932a6d0bf/web/branded-main-nav-logo630x155.png",
            "https://dfci.widen.net/content/74dbf2d2-1d7d-42a1-ba0a-403d6a65b0e1/web/magnet_recognition_logo_pms_3278.png",
            "https://dfci.widen.net/content/336fa306-616e-4ea9-8e39-7d6fdcd303eb/web/compcancercenter_v_rgb_color_badge.png",
            "https://dfci.widen.net/content/f4982a29-b2d1-4858-acdc-41c69a51adcd/web/us-news-adult-badge-2024-2025-143x140.png",
            "https://dfci.widen.net/content/fd625301-4c6c-457c-833e-ecb73ab1c1cb/web/us-news-pediatric-badge-2023-2024.png",
            "https://dfci.widen.net/content/564abc40-3275-4121-b409-143db5df0262/web/nccn_logo_stacked-01.png",
            "https://dfci.widen.net/content/ec46f092-0d9a-4bab-8c94-9d4f247e7095/web/hms-affiliate-logo-250.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2023-06-08T12:00:00+00:00",
        "summary": "",
        "meta_description": "Paul L. Nguyen, MD, MBA - Radiation Oncology",
        "meta_lang": "en",
        "meta_favicon": "/sites/default/files/favicon.ico",
        "meta_site_name": "",
        "canonical_link": "https://www.dana-farber.org/find-a-doctor/paul-l-nguyen",
        "text": "Dying with dignity: how can we deliver values-concordant end-of-life care for immigrant patients in the United States? Lancet Reg Health Am. 2024 Jul; 35:100776. View in: Pubmed\n\nLong-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol. 2024 May 17; JCO2302445. View in: Pubmed\n\nHistologically Overt Stromal Response and the Risk of Progression after Radical Prostatectomy for Prostate Cancer. Cancers (Basel). 2024 May 14; 16(10). View in: Pubmed\n\nElective Pelvic Lymph Node Radiation Therapy and the Risk of Death in Patients With Unfavorable-Risk Prostate Cancer: A Postrandomization Analysis. J Clin Oncol. 2024 May 01; JCO2302394. View in: Pubmed\n\nProstate Cancer Survivorship and Global Health-Related Quality of Life. JCO Oncol Pract. 2024 Apr 16; OP2400173. View in: Pubmed\n\nThe Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024 Apr 27; 403(10437):1683-1722. View in: Pubmed\n\nPrognostic Significance of the Cribriform Pattern in Prostate Cancer: Clinical Outcomes and Genomic Alterations. Cancers (Basel). 2024 Mar 22; 16(7). View in: Pubmed\n\nSecondary analysis of late major gastrointestinal and genitourinary toxicities in unfavorable-risk prostate cancer patients receiving docetaxel: Insights from a randomized trial. Cancer. 2024 Jul 01; 130(13):2287-2293. View in: Pubmed\n\nTrends in Utilization and Medicare Spending on Short-Course Radiation Therapy for Breast and Prostate Cancer: An Episode-Based Analysis From 2015 to 2019. Int J Radiat Oncol Biol Phys. 2024 May 01; 119(1):17-22. View in: Pubmed\n\nMajor adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study. Prostate Cancer Prostatic Dis. 2023 Dec 05. View in: Pubmed\n\nThe Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies. Eur Urol. 2024 Feb; 85(2):125-138. View in: Pubmed\n\nBurden of prostate cancer in the Middle East: A comparative analysis based on global cancer observatory data. Cancer Med. 2023 12; 12(23):21419-21425. View in: Pubmed\n\nMR-guided prostate SBRT in prostate cancer patients with low-volume metastatic disease. World J Urol. 2023 Dec; 41(12):3889-3894. View in: Pubmed\n\nModifiable risk factors for subsequent lethal prostate cancer among men with an initially negative prostate biopsy. Br J Cancer. 2023 12; 129(12):1988-2002. View in: Pubmed\n\nLeveraging national and global political determinants of health to promote equity in cancer care. J Natl Cancer Inst. 2023 10 09; 115(10):1157-1163. View in: Pubmed\n\nObserver preference of artificial intelligence-generated versus clinical prostate contours for ultrasound-based high dose rate brachytherapy. Med Phys. 2023 Oct; 50(10):5935-5943. View in: Pubmed\n\nThe Clinical Significance of Aspergillus Detected in Lower-Respiratory-Tract Samples of Critically Ill COVID-19-Positive Patients. Adv Respir Med. 2023 Sep 02; 91(5):337-349. View in: Pubmed\n\nAssessing the Feasibility of Using Artificial Intelligence-Segmented Dominant Intraprostatic Lesion for Focal Intraprostatic Boost With External Beam Radiation Therapy. Int J Radiat Oncol Biol Phys. 2024 Jan 01; 118(1):74-84. View in: Pubmed\n\nAcute toxicity comparison of magnetic resonance-guided adaptive versus fiducial or computed tomography-guided non-adaptive prostate stereotactic body radiotherapy: A systematic review and meta-analysis. Cancer. 2023 10 01; 129(19):3044-3052. View in: Pubmed\n\nMucosal CCL28 Chemokine Improves Protection against Genital Herpes through Mobilization of Antiviral Effector Memory CCR10+CD44+ CD62L-CD8+ T Cells and Memory CCR10+B220+CD27+ B Cells into the Infected Vaginal Mucosa. J Immunol. 2023 07 01; 211(1):118-129. View in: Pubmed\n\nArtificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer. NEJM Evid. 2023 Aug; 2(8):EVIDoa2300023. View in: Pubmed\n\nASO Visual Abstract: Colon Cancer Disparities in Stage at Presentation and Time to Surgery for Asian Americans, Native Hawaiians, and Pacific Islanders: A Study with Disaggregated Ethnic Groups. Ann Surg Oncol. 2023 Jun 17. View in: Pubmed\n\nDisparities in Diagnosis, Treatment Access, and Time to Treatment Among Hispanic Men With Metastatic Prostate Cancer. JCO Oncol Pract. 2023 08; 19(8):645-653. View in: Pubmed\n\nGenetic and Genomic Testing for Prostate Cancer: Beyond DNA Repair. Am Soc Clin Oncol Educ Book. 2023 May; 43:e390384. View in: Pubmed\n\nASO Author Reflections: Colon Cancer Disparities in Stage at Presentation and Time to Surgery for Asian Americans, Native Hawaiians, and Pacific Islanders. Ann Surg Oncol. 2023 09; 30(9):5506-5508. View in: Pubmed\n\nArtificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer. Res Sq. 2023 Apr 21. View in: Pubmed\n\nColon Cancer Disparities in Stage at Presentation and Time to Surgery for Asian Americans, Native Hawaiians, and Pacific Islanders: A Study with Disaggregated Ethnic Groups. Ann Surg Oncol. 2023 Sep; 30(9):5495-5505. View in: Pubmed\n\nDeterminants of widespread metastases and of metastatic tropism in patients with prostate cancer: A genomic analysis of primary and metastatic tumors. Urol Oncol. 2023 05; 41(5):253.e21-253.e26. View in: Pubmed\n\nManagement of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer. 2023 05; 185:178-215. View in: Pubmed\n\nTranscriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol Oncol. 2023 04; 6(2):224-227. View in: Pubmed\n\nUncontrolled Cardiovascular Risk Factors in Prostate Cancer Patients: Are We Leaving Too Much on the Table? JACC CardioOncol. 2023 Feb; 5(1):82-84. View in: Pubmed\n\nGaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study. PLoS One. 2023; 18(2):e0281508. View in: Pubmed\n\nAnalysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials. Int J Radiat Oncol Biol Phys. 2023 07 01; 116(3):521-529. View in: Pubmed\n\nManagement of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. Eur Urol. 2023 03; 83(3):267-293. View in: Pubmed\n\nShorter Radiation Regimens and Treatment Noncompletion Among Patients With Breast and Prostate Cancer in the United States: An Analysis of Racial Disparities in Access and Quality. JCO Oncol Pract. 2023 02; 19(2):e197-e212. View in: Pubmed\n\nDistinct Profiles of DNA Repair Activity Define Favorable-risk Prostate Cancer Subtypes With Divergent Outcome. Clin Genitourin Cancer. 2023 02; 21(1):76-83. View in: Pubmed\n\nGenomic alterations predictive of poor clinical outcomes in pan-cancer. Oncotarget. 2022; 13:1069-1077. View in: Pubmed\n\nThe Increasing Importance of Rigorous Real-World Evidence. JNCI Cancer Spectr. 2022 Aug 10. View in: Pubmed\n\nShared burden: the association between cancer diagnosis, financial toxicity, and healthcare cost-related coping mechanisms by family members of non-elderly patients in the USA. Support Care Cancer. 2022 Nov; 30(11):8905-8917. View in: Pubmed\n\nThe Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521. Int J Radiat Oncol Biol Phys. 2022 10 01; 114(2):266-274. View in: Pubmed\n\nSecond malignancy probabilities in patients with prostate cancer treated with whole pelvis radiation therapy versus prostate only radiation therapy. Prostate. 2022 08; 82(11):1098-1106. View in: Pubmed\n\nCorrigendum to definitive and sustained increase in prostate cancer metastases in the United States. Urol Oncol. 2022 Jul; 40(7):354. View in: Pubmed\n\nLocalized prostate cancer disparities in risk group at presentation and access to treatment for Hispanic men. Prostate Cancer Prostatic Dis. 2023 06; 26(2):309-316. View in: Pubmed\n\nMagnetic Resonance-Guided Prostate Stereotactic Body Radiation Therapy With Daily Online Plan Adaptation: Results of a Prospective Phase 1 Trial and Supplemental Cohort. Adv Radiat Oncol. 2022 Sep-Oct; 7(5):100934. View in: Pubmed\n\nRacial disparities in treatment delay among younger men with prostate cancer. Prostate Cancer Prostatic Dis. 2022 09; 25(3):590-592. View in: Pubmed\n\nComparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis. JAMA Netw Open. 2021 12 01; 4(12):e2139769. View in: Pubmed\n\nProstate Cancer Disparities in Risk Group at Presentation and Access to Treatment for Asian Americans, Native Hawaiians, and Pacific Islanders: A Study With Disaggregated Ethnic Groups. JCO Oncol Pract. 2022 01; 18(1):e204-e218. View in: Pubmed\n\nRadiation Dose to the Intraprostatic Urethra Correlates Strongly With Urinary Toxicity After Prostate Stereotactic Body Radiation Therapy: A Combined Analysis of 23 Prospective Clinical Trials. Int J Radiat Oncol Biol Phys. 2022 01 01; 112(1):75-82. View in: Pubmed\n\nThe Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation. Int J Radiat Oncol Biol Phys. 2022 05 01; 113(1):66-76. View in: Pubmed\n\nExercise: A Treatment That Should Be Prescribed With Radiation Therapy. Int J Radiat Oncol Biol Phys. 2022 01 01; 112(1):96-98. View in: Pubmed\n\nTrends in Incidence, and Mortality of Acute Exacerbation of Chronic Obstructive Pulmonary Disease in the United States Emergency Department (2010-2018). COPD. 2021 10; 18(5):567-575. View in: Pubmed\n\nBoosting the Abscopal Effect Using Immunogenic Biomaterials With Varying Radiation Therapy Field Sizes. Int J Radiat Oncol Biol Phys. 2022 02 01; 112(2):475-486. View in: Pubmed\n\nHigh-flow nasal cannula therapy in a predominantly African American population with COVID-19 associated acute respiratory failure. BMJ Open Respir Res. 2021 09; 8(1). View in: Pubmed\n\nNovel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). Cancer Genet. 2021 11; 258-259:61-68. View in: Pubmed\n\nSecond malignancy probabilities in prostate cancer patients treated with SBRT and other contemporary radiation techniques. Radiother Oncol. 2021 08; 161:241-250. View in: Pubmed\n\nElective Pelvic Lymph Node Radiation in Prostate Cancer Revisited. J Clin Oncol. 2021 09 01; 39(25):2845-2846. View in: Pubmed\n\nComparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. Commun Biol. 2021 06 03; 4(1):670. View in: Pubmed\n\nRacial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation. J Natl Cancer Inst. 2021 06 01; 113(6):719-726. View in: Pubmed\n\nAssociation of Medicaid expansion and insurance status, cancer stage, treatment and mortality among patients with cervical cancer. Cancer Rep (Hoboken). 2021 12; 4(6):e1407. View in: Pubmed\n\nRisk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial. Cancer. 2021 07 01; 127(13):2213-2221. View in: Pubmed\n\nClinical characterization of radiation-associated muscle-invasive bladder cancer. Urology. 2021 08; 154:208-214. View in: Pubmed\n\nValidation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. JAMA Oncol. 2021 04 01; 7(4):544-552. View in: Pubmed\n\nFinancial worry and psychological distress among cancer survivors in the United States, 2013-2018. Support Care Cancer. 2021 Sep; 29(9):5523-5535. View in: Pubmed\n\nCorrelative analysis between two commercially available post-prostatectomy genomic tests. Prostate Cancer Prostatic Dis. 2021 06; 24(2):575-577. View in: Pubmed\n\nAssessment of Simulated SARS-CoV-2 Infection and Mortality Risk Associated With Radiation Therapy Among Patients in 8 Randomized Clinical Trials. JAMA Netw Open. 2021 03 01; 4(3):e213304. View in: Pubmed\n\nIntermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. Lancet Oncol. 2021 03; 22(3):402-410. View in: Pubmed\n\nDisparities in Refusal of Locoregional Treatment for Prostate Adenocarcinoma. JCO Oncol Pract. 2021 10; 17(10):e1489-e1501. View in: Pubmed\n\nAssociation Between Travel Distance and Use of Postoperative Radiation Therapy Among Men With Organ-Confined Prostate Cancer: Does Geography Influence Treatment Decisions? Pract Radiat Oncol. 2021 Jul-Aug; 11(4):e426-e433. View in: Pubmed\n\nInitial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update. J Clin Oncol. 2021 Apr 10; 39(11):1274-1305. View in: Pubmed\n\nA Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. 2021 09; 80(3):280-292. View in: Pubmed\n\nHealth care spending in prostate cancer: An assessment of characteristics and health care utilization of high resource-patients. Urol Oncol. 2021 02; 39(2):130.e17-130.e24. View in: Pubmed\n\nA Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. Eur Urol. 2021 03; 79(3):374-383. View in: Pubmed\n\nFactors Influencing Noncompletion of Radiation Therapy Among Men With Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2021 04 01; 109(5):1279-1285. View in: Pubmed\n\nDevelopment and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. JAMA Oncol. 2020 12 01; 6(12):1912-1920. View in: Pubmed\n\nCognition and depression effects of androgen receptor axis-targeted drugs in men with prostate cancer: A systematic review. J Geriatr Oncol. 2021 06; 12(5):687-695. View in: Pubmed\n\nThe Case for Brachytherapy: Why It Deserves a Renaissance. Adv Radiat Oncol. 2021 Mar-Apr; 6(2):100605. View in: Pubmed\n\nGeneral and Health-Related Internet Use Among Cancer Survivors in the United States: A 2013-2018 Cross-Sectional Analysis. J Natl Compr Canc Netw. 2020 11; 18(11):1468-1475. View in: Pubmed\n\nDevelopment and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. JCO Precis Oncol. 2020 Nov; 4:1228-1238. View in: Pubmed\n\nAssessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer: A Systematic Review. JAMA Oncol. 2020 Nov 01; 6(11):1793-1800. View in: Pubmed\n\nUtilization of multimodality therapy with primary radical prostatectomy versus radiation therapy for Gleason 8-10 prostate cancer. Brachytherapy. 2021 Jan-Feb; 20(1):1-9. View in: Pubmed\n\nExecutive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys. 2021 03 15; 109(4):953-963. View in: Pubmed\n\nLess Is More During COVID 19. Int J Radiat Oncol Biol Phys. 2020 10 01; 108(2):339. View in: Pubmed\n\nRelative Timing of Radiotherapy and Androgen Deprivation for Prostate Cancer and Implications for Treatment During the COVID-19 Pandemic. JAMA Oncol. 2020 10 01; 6(10):1630-1632. View in: Pubmed\n\nQuantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients. Prostate Cancer Prostatic Dis. 2021 06; 24(2):414-422. View in: Pubmed\n\nImproving Diversity and Inclusion in the Post-Coronavirus Disease 2019 Era Through a Radiation Oncology Intensive Shadowing Experience (RISE). Adv Radiat Oncol. 2021 Jan-Feb; 6(1):100566. View in: Pubmed\n\nPsychological Distress and Access to Mental Health Services Among Cancer Survivors: a National Health Interview Survey Analysis. J Gen Intern Med. 2021 10; 36(10):3243-3245. View in: Pubmed\n\nRacial Differences in Genomic Profiling of Prostate Cancer. N Engl J Med. 2020 09 10; 383(11):1083-1085. View in: Pubmed\n\nDisparities in Mortality from Larynx Cancer: Implications for Reducing Racial Differences. Laryngoscope. 2021 04; 131(4):E1147-E1155. View in: Pubmed\n\nRe: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020;382:2187-96. Eur Urol. 2020 11; 78(5):e195. View in: Pubmed\n\nNRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. Int J Radiat Oncol Biol Phys. 2021 01 01; 109(1):174-185. View in: Pubmed\n\nMental Distress and Mental Health Services Receipt in Foreign-Born Survivors of Cancer: a National Health Interview Survey Analysis. J Gen Intern Med. 2021 08; 36(8):2495-2498. View in: Pubmed\n\nDevelopment and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer. Clin Genitourin Cancer. 2021 06; 19(3):246-254.e5. View in: Pubmed\n\nThree-tiered Subclassification System of High-risk Prostate Cancer in Men Managed With Radical Prostatectomy: Implications for Treatment Decision-making. Urology. 2020 11; 145:197-203. View in: Pubmed\n\nProstate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities. Prostate. 2020 09; 80(13):1128-1133. View in: Pubmed\n\nImpact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. Urol Oncol. 2020 09; 38(9):735.e9-735.e15. View in: Pubmed\n\nTo Radiate or Not to Radiate-The Challenges of Pelvic Reirradiation. Semin Radiat Oncol. 2020 Jul; 30(3):238-241. View in: Pubmed\n\nDoublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors. Int J Radiat Oncol Biol Phys. 2020 11 15; 108(4):936-940. View in: Pubmed\n\nTranscriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. Eur Urol. 2020 09; 78(3):327-332. View in: Pubmed\n\nProstate cancer management costs vary by disease stage at presentation. Prostate Cancer Prostatic Dis. 2020 12; 23(4):564-566. View in: Pubmed\n\nAddition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. J Clin Oncol. 2020 09 10; 38(26):3024-3031. View in: Pubmed\n\nAssociation of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. JAMA Oncol. 2020 05 01; 6(5):735-743. View in: Pubmed\n\nSurface applicator high-dose-rate fractionated brachytherapy for superficial cancers of the penis: A single-center case series and national database comparison. J Am Acad Dermatol. 2021 Jan; 84(1):168-172. View in: Pubmed\n\nLocal management of preinvasive and clinical T1-3 penile cancer: utilization of diverse treatment modalities. Future Oncol. 2020 May; 16(14):955-960. View in: Pubmed\n\nIntermediate-risk Prostate Cancer: Stratification and Management. Eur Urol Oncol. 2020 06; 3(3):270-280. View in: Pubmed\n\nPerformance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. Prostate Cancer Prostatic Dis. 2020 12; 23(4):646-653. View in: Pubmed\n\nGeographic Distribution of Racial Differences in Prostate Cancer Mortality. JAMA Netw Open. 2020 03 02; 3(3):e201839. View in: Pubmed\n\nChanges in Length and Complexity of Clinical Practice Guidelines in Oncology, 1996-2019. JAMA Netw Open. 2020 03 02; 3(3):e200841. View in: Pubmed\n\nEarly Impact of the Affordable Care Act and Medicaid Expansion on Racial and Socioeconomic Disparities in Cancer Care. Am J Clin Oncol. 2020 03; 43(3):163-167. View in: Pubmed\n\nMaster Protocol Trial Design for Efficient and Rational Evaluation of Novel Therapeutic Oncology Devices. J Natl Cancer Inst. 2020 03 01; 112(3):229-237. View in: Pubmed\n\nValidation of a subclassification for high-risk prostate cancer in a prospective cohort. Cancer. 2020 05 15; 126(10):2132-2138. View in: Pubmed\n\nTrends, Quality, and Readability of Online Health Resources on Proton Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 05 01; 107(1):33-38. View in: Pubmed\n\nPhysician and facility drivers of spending variation in locoregional prostate cancer. Cancer. 2020 04 15; 126(8):1622-1631. View in: Pubmed\n\nGenomic and clinical characterization of stromal infiltration markers in prostate cancer. Cancer. 2020 04 01; 126(7):1407-1412. View in: Pubmed\n\nAddition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer. Ann Oncol. 2012 Sep; 23(9):2346-2352. View in: Pubmed\n\nProstate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012. Cancer. 2020 02 15; 126(4):717-724. View in: Pubmed\n\nAn Update to Changing Patterns of Anal Carcinoma in the United States. Am J Clin Oncol. 2019 12; 42(12):887-897. View in: Pubmed\n\nRisk of dementia following androgen deprivation therapy for treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2020 09; 23(3):410-418. View in: Pubmed\n\nLocal Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. Eur Urol. 2020 02; 77(2):201-208. View in: Pubmed\n\nRisk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy. Eur Urol Oncol. 2021 02; 4(1):66-72. View in: Pubmed\n\nCombined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer. J Urol. 2019 11; 202(5):973-978. View in: Pubmed\n\nUnited States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015. Prostate Cancer Prostatic Dis. 2020 03; 23(1):179-183. View in: Pubmed\n\nTranscriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer. Clin Cancer Res. 2019 11 15; 25(22):6721-6730. View in: Pubmed\n\nDefinitive and sustained increase in prostate cancer metastases in the United States. Urol Oncol. 2019 12; 37(12):988-990. View in: Pubmed\n\nComparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. J Natl Compr Canc Netw. 2019 09 01; 17(9):1049-1058. View in: Pubmed\n\nUsing Stereotactic Body Radiotherapy to Overcome the Radioresistant Reputation of Renal Cell Carcinoma. Eur Urol Oncol. 2019 09; 2(5):524-525. View in: Pubmed\n\nPractice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level. J Natl Compr Canc Netw. 2019 08 01; 17(8):941-948. View in: Pubmed\n\nGenomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2019 11 01; 105(3):621-627. View in: Pubmed\n\nAssociation of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. JAMA Oncol. 2019 07 01; 5(7):975-983. View in: Pubmed\n\nConservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. Cancer. 2019 10 01; 125(19):3338-3346. View in: Pubmed\n\nCardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer. J Am Coll Cardiol. 2019 06 18; 73(23):2976-2987. View in: Pubmed\n\nTranscriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. Eur Urol Oncol. 2019 07; 2(4):405-412. View in: Pubmed\n\nAssociation of Treatment With 5a-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer. JAMA Intern Med. 2019 06 01; 179(6):812-819. View in: Pubmed\n\nUse and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer. Cancer. 2019 09 15; 125(18):3164-3171. View in: Pubmed\n\nActive Surveillance for Low-Risk Prostate Cancer in Black Patients. N Engl J Med. 2019 05 23; 380(21):2070-2072. View in: Pubmed\n\nThe current landscape of low-value care in men diagnosed with prostate cancer: what is the role of individual hospitals? Urol Oncol. 2019 09; 37(9):575.e9-575.e18. View in: Pubmed\n\nQuality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2019 May 01; 5(5):664-670. View in: Pubmed\n\nEvolution of Radiation Oncology in Pakistan. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):11-16. View in: Pubmed\n\nNovel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. Clin Cancer Res. 2019 Jul 15; 25(14):4290-4299. View in: Pubmed\n\nProstate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. Eur Urol. 2020 01; 77(1):3-10. View in: Pubmed\n\nStereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. Int J Radiat Oncol Biol Phys. 2019 07 15; 104(4):778-789. View in: Pubmed\n\nFacility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. J Urol. 2019 04; 201(4):728-734. View in: Pubmed\n\nQuality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. J Urol. 2019 04; 201(4):735-741. View in: Pubmed\n\nThe Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. J Natl Cancer Inst. 2019 03 01; 111(3):301-310. View in: Pubmed\n\nAntiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B. J Med Virol. 2019 07; 91(7):1288-1294. View in: Pubmed\n\nReadressing the rationale of irradiation in stage I seminoma guidelines: a critical essay. BJU Int. 2019 07; 124(1):35-39. View in: Pubmed\n\nUse of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015. JAMA. 2019 Feb 19; 321(7):704-706. View in: Pubmed\n\nA National Survey of Radiation Oncologists and Urologists on Perceived Attitudes and Recommendations of Active Surveillance for Low-Risk Prostate Cancer. Clin Genitourin Cancer. 2019 06; 17(3):e472-e481. View in: Pubmed\n\nUnderutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. Eur Urol Oncol. 2021 04; 4(2):327-330. View in: Pubmed\n\nPostoperative Radiation Therapy in Localized Prostate Cancer: When, How Much, and How Fast? Int J Radiat Oncol Biol Phys. 2019 02 01; 103(2):289-292. View in: Pubmed\n\nProstate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Scores. Eur Urol. 2019 06; 75(6):1038-1040. View in: Pubmed\n\nImpact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival? Cancer. 2019 04 15; 125(8):1319-1329. View in: Pubmed\n\nA comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer. Brachytherapy. 2019 Mar - Apr; 18(2):186-191. View in: Pubmed\n\nEvaluating the influence of prostate-specific antigen kinetics on metastasis in men with PSA recurrence after partial gland therapy. Brachytherapy. 2019 Mar - Apr; 18(2):198-203. View in: Pubmed\n\nIncreased Risk of Infectious Complications in Older Patients With Indolent Non-Hodgkin Lymphoma Exposed to Bendamustine. Clin Infect Dis. 2019 01 07; 68(2):247-255. View in: Pubmed\n\nClinical Features Associated with Survival Outcome in African-American Patients with Hepatocellular Carcinoma. Am J Gastroenterol. 2019 01; 114(1):80-88. View in: Pubmed\n\nClinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. Clin Cancer Res. 2019 04 15; 25(8):2450-2457. View in: Pubmed\n\nReply to Partial gland therapy for prostate cancer. Cancer. 2019 03 01; 125(5):819-820. View in: Pubmed\n\nCorrection: Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis. PLoS One. 2018; 13(12):e0209715. View in: Pubmed\n\nPelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review. Eur Urol. 2019 03; 75(3):464-476. View in: Pubmed\n\nNeoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. Ann Surg Oncol. 2019 Jan; 26(1):297-305. View in: Pubmed\n\nImpact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic Review. Eur Urol Oncol. 2019 05; 2(3):265-273. View in: Pubmed\n\nImpact of Health Insurance Status on Prostate Cancer Treatment Modality Selection in the United States. Am J Clin Oncol. 2018 Nov; 41(11):1062-1068. View in: Pubmed\n\nAndrogen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. Eur Urol. 2019 01; 75(1):35-41. View in: Pubmed\n\nRising Inpatient Encounters and Economic Burden for Patients with Nonalcoholic Fatty Liver Disease in the USA. Dig Dis Sci. 2019 03; 64(3):698-707. View in: Pubmed\n\nMechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer. Am J Physiol Endocrinol Metab. 2018 12 01; 315(6):E1185-E1193. View in: Pubmed\n\nAssociation Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic Cancer. Ann Surg Oncol. 2018 Dec; 25(13):4027-4034. View in: Pubmed\n\nTravel Distance as a Barrier to Receipt of Adjuvant Radiation Therapy After Radical Prostatectomy. Am J Clin Oncol. 2018 10; 41(10):953-959. View in: Pubmed\n\nClinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. J Clin Oncol. 2018 Nov 10; 36(32):3251-3258. View in: Pubmed\n\n'Reply to the letter to the editor 'Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer' by Yang et al.' by V. Conteduca, U. De giorgi and G. Lauletta. Ann Oncol. 2018 09 01; 29(9):2021-2022. View in: Pubmed\n\nRecommendations of Active Surveillance for Intermediate-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Eur Urol Oncol. 2019 03; 2(2):189-195. View in: Pubmed\n\nEvaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. Prostate Cancer Prostatic Dis. 2019 03; 22(1):125-136. View in: Pubmed\n\nMRI guided focal HDR brachytherapy for localized prostate cancer: Toxicity, biochemical outcome and quality of life. Radiother Oncol. 2018 12; 129(3):554-560. View in: Pubmed\n\nThe Long and Short of It: New Lessons on the Optimal Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer and Where We Need to Go From Here. Int J Radiat Oncol Biol Phys. 2018 08 01; 101(5):1014-1017. View in: Pubmed\n\nDuctal carcinoma in situ on core needle biopsy only with no residual disease at surgery. Breast J. 2018 11; 24(6):971-975. View in: Pubmed\n\nReply to John T. Leppert and James D. Brooks' Letter to the Editor re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol 2018;74:146-54. Eur Urol. 2018 11; 74(5):e112-e113. View in: Pubmed\n\nLong-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancer. Cancer. 2018 09 01; 124(17):3528-3535. View in: Pubmed\n\nHigher mortality and hospital charges in patients with cirrhosis and acute respiratory illness: a population-based study. Sci Rep. 2018 07 02; 8(1):9969. View in: Pubmed\n\nDetermining optimal eluter design by modeling physical dose enhancement in brachytherapy. Med Phys. 2018 Jun 15. View in: Pubmed\n\nAssociation Between Androgen Deprivation Therapy and Patient-reported Depression in Men With Recurrent Prostate Cancer. Clin Genitourin Cancer. 2018 08; 16(4):313-317. View in: Pubmed\n\nFunding Support and Principal Investigator Leadership of Oncology Clinical Trials Using Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018 09 01; 102(1):34-43. View in: Pubmed\n\nWelcome to European Urology Oncology: Your New Journal, Where Multiple Disciplines Meet To Improve Care of Patients with Genitourinary Cancers. Eur Urol Oncol. 2018 05; 1(1):1-2. View in: Pubmed\n\nOptimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer. Eur Urol Oncol. 2018 05; 1(1):3-18. View in: Pubmed\n\nDevelopment and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. Clin Cancer Res. 2018 08 15; 24(16):3908-3916. View in: Pubmed\n\nHigher risk of hepatocellular carcinoma in Hispanic patients with hepatitis C cirrhosis and metabolic risk factors. Sci Rep. 2018 05 08; 8(1):7164. View in: Pubmed\n\nThree-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy. Cancer. 2018 07 15; 124(14):2939-2947. View in: Pubmed\n\nProstate Cancer - Local Treatment after Radiorecurrence: Surgery - Back to the future? Int Braz J Urol. 2018 May-Jun; 44(3):433-434. View in: Pubmed\n\nEconomic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis. PLoS One. 2018; 13(4):e0196452. View in: Pubmed\n\nAndrogen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer. J Endocr Soc. 2018 May 01; 2(5):485-496. View in: Pubmed\n\nLiver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. J Urol. 2018 09; 200(3):573-581. View in: Pubmed\n\nClinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. Int J Radiat Oncol Biol Phys. 2018 07 15; 101(4):883-888. View in: Pubmed\n\nImpact of Radiation Therapy Dose Escalation on Prostate Cancer Outcomes and Toxicities. Am J Clin Oncol. 2018 04; 41(4):409-415. View in: Pubmed\n\nIn Reply to Ong et al. Int J Radiat Oncol Biol Phys. 2018 04 01; 100(5):1295. View in: Pubmed\n\nIncreased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. Am J Med. 2018 05; 131(5):517-523. View in: Pubmed\n\nRadical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. JAMA. 2018 03 06; 319(9):896-905. View in: Pubmed\n\nLaboratory Eligibility Criteria as Potential Barriers to Participation by Black Men in Prostate Cancer Clinical Trials. JAMA Oncol. 2018 Mar 01; 4(3):413-414. View in: Pubmed\n\nClinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol. 2018 08; 74(2):146-154. View in: Pubmed\n\nAndrogen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer. Ann Oncol. 2018 02 01; 29(2):386-391. View in: Pubmed\n\nAdjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. JAMA Oncol. 2018 Feb 01; 4(2):225-229. View in: Pubmed\n\nPatient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018 06 01; 101(2):376-386. View in: Pubmed\n\nReply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermanns' Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-70. Eur Urol. 2018 04; 73(4):e96-e97. View in: Pubmed\n\nAssociation of Androgen Deprivation Therapy and Thromboembolic Events: A Systematic Review and Meta-analysis. Urology. 2018 04; 114:155-162. View in: Pubmed\n\nThe Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort. Eur Urol Focus. 2019 05; 5(3):474-481. View in: Pubmed\n\nContemporary Incidence and Outcomes of Prostate Cancer Lymph Node Metastases. J Urol. 2018 06; 199(6):1510-1517. View in: Pubmed\n\nBrachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer. Urol Oncol. 2018 04; 36(4):157.e15-157.e20. View in: Pubmed\n\nOptimizing androgen deprivation therapy with radiation therapy for aggressive localized and locally advanced prostate cancer. Urol Oncol. 2021 10; 39(10):720-727. View in: Pubmed\n\nTravel distance and stereotactic body radiotherapy for localized prostate cancer. Cancer. 2018 03 15; 124(6):1141-1149. View in: Pubmed\n\nPerformance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. Eur Urol. 2018 07; 74(1):107-114. View in: Pubmed\n\nFocal MRI-Guided Salvage High-Dose-Rate Brachytherapy in Patients With Radiorecurrent Prostate Cancer. Technol Cancer Res Treat. 2017 12; 16(6):1194-1201. View in: Pubmed\n\nAssociations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncol. 2017 12 01; 3(12):1663-1672. View in: Pubmed\n\nDevelopment and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. J Clin Oncol. 2018 02 20; 36(6):581-590. View in: Pubmed\n\nPathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance. Clin Genitourin Cancer. 2018 06; 16(3):226-234. View in: Pubmed\n\nReply to Aditya Bagrodia, Solomon Woldu, David F. Penson, Alexander Kutikov, and Samuel D. Kaffenberger's Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-70. Eur Urol. 2018 04; 73(4):e100-e101. View in: Pubmed\n\nMore advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma. Liver Int. 2018 05; 38(5):895-902. View in: Pubmed\n\nApproach to the Patient with High-Risk Prostate Cancer. Urol Clin North Am. 2017 Nov; 44(4):635-645. View in: Pubmed\n\nProstate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance. Cancer. 2018 02 15; 124(4):752-759. View in: Pubmed\n\nCreation of a Novel Digital Rectal Examination Evaluation Instrument to Teach and Assess Prostate Examination Proficiency. J Surg Educ. 2018 Mar - Apr; 75(2):434-441. View in: Pubmed\n\nEffects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer. J Pain Symptom Manage. 2018 02; 55(2):307-317.e1. View in: Pubmed\n\nVariation in the use of active surveillance for low-risk prostate cancer. Cancer. 2018 Jan 01; 124(1):55-64. View in: Pubmed\n\nLack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy. Int J Radiat Oncol Biol Phys. 2018 01 01; 100(1):53-58. View in: Pubmed\n\nEfficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis. Eur Urol. 2018 Mar; 73(3):452-461. View in: Pubmed\n\nRegional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis. PLoS One. 2017; 12(9):e0183851. View in: Pubmed\n\nReceipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer. Cancer. 2017 Dec 15; 123(24):4832-4840. View in: Pubmed\n\nAssociation of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and meta-analysis. Urol Oncol. 2017 11; 35(11):664.e1-664.e9. View in: Pubmed\n\nRacial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics. Eur Urol. 2018 Mar; 73(3):445-451. View in: Pubmed\n\nLack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017 11 15; 99(4):904-911. View in: Pubmed\n\nAssociation between androgen deprivation therapy and anxiety among 78 000 patients with localized prostate cancer. Int J Urol. 2017 10; 24(10):743-748. View in: Pubmed\n\nA novel approach to an automated needle insertion in brachytherapy procedures. Med Biol Eng Comput. 2018 Feb; 56(2):273-287. View in: Pubmed\n\nA Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol. 2018 02; 73(2):156-165. View in: Pubmed\n\nThe Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE® Military Database. J Urol. 2017 12; 198(6):1295-1300. View in: Pubmed\n\nContemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol. 2018 02; 73(2):262-270. View in: Pubmed\n\nAdjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer. Curr Urol Rep. 2017 Jul; 18(7):55. View in: Pubmed\n\nThe evolution of brachytherapy for prostate cancer. Nat Rev Urol. 2017 Jun 30; 14(7):415-439. View in: Pubmed\n\nRisk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer. Eur Urol Focus. 2019 01; 5(1):69-76. View in: Pubmed\n\nSurvival and Complications Following Surgery and Radiation for Localized Prostate Cancer: An International Collaborative Review. Eur Urol. 2018 01; 73(1):11-20. View in: Pubmed\n\nWeight change, obesity and risk of prostate cancer progression among men with clinically localized prostate cancer. Int J Cancer. 2017 09 01; 141(5):933-944. View in: Pubmed\n\nLow rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. Urol Oncol. 2017 09; 35(9):542.e25-542.e32. View in: Pubmed\n\nAbility of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. Eur Urol. 2017 11; 72(5):845-852. View in: Pubmed\n\nRacial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Ann Oncol. 2017 05 01; 28(5):1098-1104. View in: Pubmed\n\nCharacteristics and national trends of patients receiving treatment of the primary tumor for metastatic prostate cancer. Prostate Int. 2017 Sep; 5(3):89-94. View in: Pubmed\n\nComparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. Eur Urol. 2017 10; 72(4):483-487. View in: Pubmed\n\nIncreased Prevalence of Metabolic Risk Factors in Asian Americans With Hepatocellular Carcinoma. J Clin Gastroenterol. 2017 Apr; 51(4):384-390. View in: Pubmed\n\nCost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy. Eur Urol. 2017 11; 72(5):712-735. View in: Pubmed\n\nAndrogen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2017 09; 20(3):259-264. View in: Pubmed\n\nACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):437-454. View in: Pubmed\n\nNational Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):338-343. View in: Pubmed\n\nRacial Disparities in Prostate Cancer Outcome among Prostate-Specific Antigen Screening Eligible Populations in the United States. Ann Oncol. 2017 Feb 08. View in: Pubmed\n\nReal-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease. Medicine (Baltimore). 2017 Feb; 96(6):e6128. View in: Pubmed\n\nACR Appropriateness Criteria® Locally Advanced, High-Risk Prostate Cancer. Am J Clin Oncol. 2017 02; 40(1):1-10. View in: Pubmed\n\nA Monte Carlo study of I-125 prostate brachytherapy with gold nanoparticles: dose enhancement with simultaneous rectal dose sparing via radiation shielding. Phys Med Biol. 2017 03 07; 62(5):1935-1948. View in: Pubmed\n\nUtilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2017 06; 20(2):186-192. View in: Pubmed\n\nCharacterization of efficacy and toxicity after high-dose pelvic reirradiation with palliative intent for genitourinary second malignant neoplasms or local recurrences after full-dose radiation therapy in the pelvis: A high-volume cancer center experience. Adv Radiat Oncol. 2017 Apr-Jun; 2(2):140-147. View in: Pubmed\n\nPan-Cancer Analysis of Genomic Sequencing Among the Elderly. Int J Radiat Oncol Biol Phys. 2017 07 15; 98(4):726-732. View in: Pubmed\n\nImpact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. Cancer. 2017 May 01; 123(9):1536-1544. View in: Pubmed\n\nACR appropriateness criteria: Permanent source brachytherapy for prostate cancer. Brachytherapy. 2017 Mar - Apr; 16(2):266-276. View in: Pubmed\n\nDisparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. Clin Genitourin Cancer. 2017 10; 15(5):563-569.e3. View in: Pubmed\n\nACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II. Adv Radiat Oncol. 2017 Jan-Mar; 2(1):62-84. View in: Pubmed\n\nValue of Extra-Early Initiation of Salvage Radiation for Increasing Prostate-Specific Antigen After Prostatectomy. J Clin Oncol. 2016 Oct 20; 34(30):3597-3599. View in: Pubmed\n\nDevelopment and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncol. 2016 Nov; 17(11):1612-1620. View in: Pubmed\n\nEfficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. J Clin Oncol. 2016 10 10; 34(29):3529-3536. View in: Pubmed\n\nOptimization of the Radiation Management of High-Risk Prostate Cancer. Semin Radiat Oncol. 2017 01; 27(1):43-49. View in: Pubmed\n\nPrognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm. J Urol. 2017 02; 197(2):363-368. View in: Pubmed\n\nFactors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy. 2016 Nov - Dec; 15(6):695-700. View in: Pubmed\n\nThe Missing Pieces in Reporting of Randomized Controlled Trials of External Beam Radiation Therapy Dose Escalation for Prostate Cancer. Am J Clin Oncol. 2016 08; 39(4):321-6. View in: Pubmed\n\nThe Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-risk Prostate Cancer. Am J Clin Oncol. 2016 08; 39(4):368-73. View in: Pubmed\n\nMaximizing resources in the local treatment of prostate cancer: A summary of cost-effectiveness studies. Urol Oncol. 2017 02; 35(2):76-85. View in: Pubmed\n\nProstate Brachytherapy Case Volumes by Academic and Nonacademic Practices: Implications for Future Residency Training. Int J Radiat Oncol Biol Phys. 2016 11 01; 96(3):624-8. View in: Pubmed\n\nSex differences in disease presentation, treatment and clinical outcomes of patients with hepatocellular carcinoma: a single-centre cohort study. BMJ Open Gastroenterol. 2016; 3(1):e000107. View in: Pubmed\n\nNational sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers? Cancer. 2016 Nov 15; 122(21):3371-3377. View in: Pubmed\n\nDeterminants of cancer screening in Asian-Americans. Cancer Causes Control. 2016 08; 27(8):989-98. View in: Pubmed\n\nSurvival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. J Clin Oncol. 2016 09 20; 34(27):3267-75. View in: Pubmed\n\nThe decreased use of brachytherapy boost for intermediate and high-risk prostate cancer despite evidence supporting its effectiveness. Brachytherapy. 2016 Nov - Dec; 15(6):701-706. View in: Pubmed\n\nRecent relocation and decreased survival following a cancer diagnosis. Prev Med. 2016 08; 89:245-250. View in: Pubmed\n\nAssociation Between Travel Distance and Choice of Treatment for Prostate Cancer: Does Geography Reduce Patient Choice? Int J Radiat Oncol Biol Phys. 2016 10 01; 96(2):313-317. View in: Pubmed\n\nUse, complications, and costs of stereotactic body radiotherapy for localized prostate cancer. Cancer. 2016 08 15; 122(16):2496-504. View in: Pubmed\n\nThe influence of marital status on the use of breast, cervical, and colorectal cancer screening. Prev Med. 2016 08; 89:140-145. View in: Pubmed\n\nSurgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. J Urol. 2016 Oct; 196(4):1090-5. View in: Pubmed\n\nAssociation of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. J Clin Oncol. 2016 06 01; 34(16):1905-12. View in: Pubmed\n\nRandomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol. 2016 07 10; 34(20):2325-32. View in: Pubmed\n\nPatient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. JAMA Oncol. 2016 Apr; 2(4):471-80. View in: Pubmed\n\nVariation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. J Natl Compr Canc Netw. 2016 04; 14(4):421-8. View in: Pubmed\n\nComparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy. JAMA Oncol. 2016 Apr; 2(4):500-7. View in: Pubmed\n\nIndividual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes. Eur Urol Focus. 2016 Dec; 2(5):532-539. View in: Pubmed\n\nACR Appropriateness Criteria Renal Cell Carcinoma Staging. J Am Coll Radiol. 2016 May; 13(5):518-25. View in: Pubmed\n\nRethinking the Balance of Risk and Benefit of Androgen Deprivation Therapy for Intermediate-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016 Apr 01; 94(5):975-7. View in: Pubmed\n\nHigh-Dose-Rate Monotherapy for Localized Prostate Cancer-What More Will It Take to Make This a Standard Therapy? Int J Radiat Oncol Biol Phys. 2016 Mar 15; 94(4):655-6. View in: Pubmed\n\nNational trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. Cancer. 2016 05 15; 122(10):1505-12. View in: Pubmed\n\nCommon variation in BRCA1 may have a role in progression to lethal prostate cancer after radiation treatment. Prostate Cancer Prostatic Dis. 2016 06; 19(2):197-201. View in: Pubmed\n\nAssociation Between Very Small Tumor Size and Increased Cancer-Specific Mortality in Node-Positive Colon Cancer. Dis Colon Rectum. 2016 Mar; 59(3):187-93. View in: Pubmed\n\nBrachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer. J Contemp Brachytherapy. 2016 Feb; 8(1):1-6. View in: Pubmed\n\nData on Medicare eligibility and cancer screening utilization. Data Brief. 2016 Jun; 7:679-81. View in: Pubmed\n\nRelationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer. Int J Urol. 2016 Apr; 23(4):305-11. View in: Pubmed\n\nThe impact of Medicare eligibility on cancer screening behaviors. Prev Med. 2016 Apr; 85:47-52. View in: Pubmed\n\nEditorial comment. Urology. 2016 Jan; 87:152. View in: Pubmed\n\nFeasibility of brachytherapy as monotherapy for high-volume, low-risk prostate cancer. J Cancer Res Ther. 2016 Jan-Mar; 12(1):406-10. View in: Pubmed\n\nRacial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. JAMA Oncol. 2016 Jan; 2(1):85-93. View in: Pubmed\n\nAsian Americans and prostate cancer: A nationwide population-based analysis. Urol Oncol. 2016 May; 34(5):233.e7-15. View in: Pubmed\n\nDuration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. Clin Genitourin Cancer. 2016 08; 14(4):e299-305. View in: Pubmed\n\nAssociation Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016 Mar 15; 94(4):683-90. View in: Pubmed\n\nThe Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer. Clin Cancer Res. 2016 Apr 01; 22(7):1777-86. View in: Pubmed\n\nRacial/Ethnic Disparities in Perioperative Outcomes of Major Procedures: Results From the National Surgical Quality Improvement Program. Ann Surg. 2015 Dec; 262(6):955-64. View in: Pubmed\n\nA prospective study of nomogram-based adaptation of prostate radiotherapy target volumes. Radiat Oncol. 2015 Nov 25; 10:243. View in: Pubmed\n\nDeterminants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary Era. J Urol. 2016 04; 195(4 Pt 1):913-8. View in: Pubmed\n\nProstate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations. JAMA. 2015 Nov 17; 314(19):2077-9. View in: Pubmed\n\nClosing the Cancer Divide Through Ubuntu: Information and Communication Technology-Powered Models for Global Radiation Oncology. Int J Radiat Oncol Biol Phys. 2016 Mar 01; 94(3):440-9. View in: Pubmed\n\nSignificant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. Urol Oncol. 2016 Feb; 34(2):57.e15-22. View in: Pubmed\n\nSignificant association of brachytherapy boost with reduced prostate cancer-specific mortality in contemporary patients with localized, unfavorable-risk prostate cancer. Brachytherapy. 2015 Nov-Dec; 14(6):773-80. View in: Pubmed\n\nDevelopment of a standard survivorship care plan template for radiation oncologists. Pract Radiat Oncol. 2016 Jan-Feb; 6(1):57-65. View in: Pubmed\n\nOccult High-risk Disease in Clinically Low-risk Prostate Cancer with =50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk? Urology. 2016 Jan; 87:125-32. View in: Pubmed\n\nSuicide and accidental deaths among patients with non-metastatic prostate cancer. BJU Int. 2016 Aug; 118(2):286-97. View in: Pubmed\n\nAssociation of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer. Cancer. 2016 Jan 01; 122(1):78-83. View in: Pubmed\n\nRacial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study. J Natl Compr Canc Netw. 2015 Sep; 13(9):1131-8. View in: Pubmed\n\nAssociation between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. BJU Int. 2016 Aug; 118(2):279-85. View in: Pubmed\n\nContemporary nationwide patterns of self-reported prostate-specific antigen screening in US veterans. Urol Oncol. 2015 Dec; 33(12):503.e7-15. View in: Pubmed\n\nPopulation-based assessment of determining predictors for quality of prostate cancer surveillance. Cancer. 2015 Dec 01; 121(23):4150-7. View in: Pubmed\n\nTemporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. Urol Oncol. 2015 Dec; 33(12):504.e9-17. View in: Pubmed\n\nGleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9? BJU Int. 2016 Jul; 118(1):95-101. View in: Pubmed\n\nConditional cancer-specific mortality in T4, N1, or M1 prostate cancer: implications for long-term prognosis. Radiat Oncol. 2015 Jul 30; 10:155. View in: Pubmed\n\nDefinition and Validation of \"Favorable High-Risk Prostate Cancer\": Implications for Personalizing Treatment of Radiation-Managed Patients. Int J Radiat Oncol Biol Phys. 2015 Nov 15; 93(4):828-35. View in: Pubmed\n\nMedical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged =66 years. Eur J Surg Oncol. 2015 Nov; 41(11):1529-39. View in: Pubmed\n\nImpact of a Genomic Classifier of Metastatic Risk on Postprostatectomy Treatment Recommendations by Radiation Oncologists and Urologists. Urology. 2015 Jul; 86(1):35-40. View in: Pubmed\n\nAssociation Between Older Age and Increasing Gleason Score. Clin Genitourin Cancer. 2015 Dec; 13(6):525-30.e1-3. View in: Pubmed\n\nAn evaluation of the 'weekend effect' in patients admitted with metastatic prostate cancer. BJU Int. 2015 Dec; 116(6):911-9. View in: Pubmed\n\nRisk of prostate cancer mortality in men with a history of prior cancer. BJU Int. 2016 06; 117(6B):E20-8. View in: Pubmed\n\nASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26. Blood Cancer J. 2015 May 22; 5:e315. View in: Pubmed\n\nHigh-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer. Prostate Cancer Prostatic Dis. 2015 Sep; 18(3):229-36. View in: Pubmed\n\nDifferential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. Urol Oncol. 2015 Jul; 33(7):330.e19-25. View in: Pubmed\n\nShared decision making and use of decision AIDS for localized prostate cancer : perceptions from radiation oncologists and urologists. JAMA Intern Med. 2015 May; 175(5):792-9. View in: Pubmed\n\nHigh PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy? Ann Oncol. 2015 Jul; 26(7):1390-5. View in: Pubmed\n\nAndrogen deprivation therapy reversibly increases endothelium-dependent vasodilation in men with prostate cancer. J Am Heart Assoc. 2015 Apr 20; 4(4). View in: Pubmed\n\nA refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion. Ann Oncol. 2015 Jul; 26(7):1396-401. View in: Pubmed\n\nShifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancer. Brachytherapy. 2015 Jul-Aug; 14(4):511-6. View in: Pubmed\n\nFatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2015 Aug; 95(2):251-63. View in: Pubmed\n\nOpen-source image registration for MRI-TRUS fusion-guided prostate interventions. Int J Comput Assist Radiol Surg. 2015 Jun; 10(6):925-34. View in: Pubmed\n\nCancer-specific mortality of Asian Americans diagnosed with cancer: a nationwide population-based assessment. J Natl Cancer Inst. 2015 Jun; 107(6):djv054. View in: Pubmed\n\nThe blue light-dependent phosphorylation of the CCE domain determines the photosensitivity of Arabidopsis CRY2. Mol Plant. 2015 04; 8(4):631-43. View in: Pubmed\n\nThe TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer. Prostate. 2015 Jun 15; 75(9):897-906. View in: Pubmed\n\nIncidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. J Urol. 2015 Aug; 194(2):343-9. View in: Pubmed\n\nBrachytherapy: where has it gone? J Clin Oncol. 2015 Mar 20; 33(9):980-2. View in: Pubmed\n\nBurden of hospital admissions and utilization of hospice care in metastatic prostate cancer patients. Urology. 2015 Feb; 85(2):343-9. View in: Pubmed\n\nPotential for information and communication technologies to catalyze global collaborations in radiation oncology. Int J Radiat Oncol Biol Phys. 2015 Feb 01; 91(2):444-7. View in: Pubmed\n\nRadiation therapy for node-positive prostate cancer: it's time for a randomized trial. Oncology (Williston Park). 2015 Feb; 29(2):116-7. View in: Pubmed\n\nWho bears the greatest burden of aggressive treatment of indolent prostate cancer? Am J Med. 2015 Jun; 128(6):609-16. View in: Pubmed\n\nGermLine Variation in Superoxide Dismutase-2 (SOD2) and Survival Outcomes After Radiation Therapy for Prostate Cancer: Results of a Test and Validation Set Analysis. Clin Genitourin Cancer. 2015 Aug; 13(4):370-377.e1. View in: Pubmed\n\nCost implications and complications of overtreatment of low-risk prostate cancer in the United States. J Natl Compr Canc Netw. 2015 Jan; 13(1):61-8. View in: Pubmed\n\nToward personalizing the use of androgen deprivation therapy to maximize benefit and minimize harm. Eur Urol. 2015 Sep; 68(3):397-8. View in: Pubmed\n\nCongestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol. 2015 May; 94(2):228-37. View in: Pubmed\n\nNational trends in the recommendation of radiotherapy after prostatectomy for prostate cancer before and after the reporting of a survival benefit in March 2009. Clin Genitourin Cancer. 2015 Jun; 13(3):e167-72. View in: Pubmed\n\nBrachytherapy application with in situ dose painting administered by gold nanoparticle eluters. Int J Radiat Oncol Biol Phys. 2015 Feb 01; 91(2):385-92. View in: Pubmed\n\nACR appropriateness Criteria® Postradical prostatectomy irradiation in prostate cancer. Oncology (Williston Park). 2014 Dec; 28(12):1125-30, 1132-6. View in: Pubmed\n\nIncidence and determinants of 1-month mortality after cancer-directed surgery. Ann Oncol. 2015 Feb; 26(2):399-406. View in: Pubmed\n\nHepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2015 Mar; 93(3):257-76. View in: Pubmed\n\nThe burden of skeletal-related events in patients with prostate cancer and bone metastasis. Urol Oncol. 2015 Jan; 33(1):17.e9-17.e18. View in: Pubmed\n\nAssociation of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int. 2015 Sep; 116(3):358-65. View in: Pubmed\n\nPatterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer. Eur Urol. 2015 Jul; 68(1):32-9. View in: Pubmed\n\nThe association between race and treatment regret among men with recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2015 Mar; 18(1):38-42. View in: Pubmed\n\nIndependent brachytherapy plan verification software: improving efficacy and efficiency. Radiother Oncol. 2014 Dec; 113(3):420-4. View in: Pubmed\n\nImproving the efficiency of a block schedule for treatment planning simulation in a radiation oncology department. J Clin Oncol. 2014 Oct 20; 32(30_suppl):158. View in: Pubmed\n\nIncidence and determinants of 1-month mortality after cancer-directed surgery. J Clin Oncol. 2014 Oct 20; 32(30_suppl):282. View in: Pubmed\n\nIncome inequality and treatment of African American men with high-risk prostate cancer. Urol Oncol. 2015 Jan; 33(1):18.e7-18.e13. View in: Pubmed\n\nVariation in pelvic lymph node dissection among patients undergoing radical prostatectomy by hospital characteristics and surgical approach: results from the National Cancer Database. J Urol. 2015 Mar; 193(3):820-5. View in: Pubmed\n\nVariability in MRI vs. ultrasound measures of prostate volume and its impact on treatment recommendations for favorable-risk prostate cancer patients: a case series. Radiat Oncol. 2014 Sep 09; 9:200. View in: Pubmed\n\nEarly radiotherapy after radical prostatectomy improves cancer-specific survival only in patients with highly aggressive prostate cancer: validation of recently released criteria. Int J Urol. 2015 Jan; 22(1):89-95. View in: Pubmed\n\nMental health outcomes in elderly men with prostate cancer. Urol Oncol. 2014 Nov; 32(8):1333-40. View in: Pubmed\n\nAdverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015 May; 67(5):825-36. View in: Pubmed\n\nPopulation-based assessment of prostate-specific antigen testing for prostate cancer in the elderly. Urol Oncol. 2015 Feb; 33(2):69.e29-34. View in: Pubmed\n\nThe association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):273-9. View in: Pubmed\n\nPerceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Med Care. 2014 Jul; 52(7):579-85. View in: Pubmed\n\nRole of androgen deprivation therapy in early salvage radiation among patients with prostate-specific antigen level of 0.5 or less. Clin Genitourin Cancer. 2015 Feb; 13(1):e1-6. View in: Pubmed\n\nTrends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. Urology. 2014 Aug; 84(2):386-92. View in: Pubmed\n\nCurrent clinical presentation and treatment of localized prostate cancer in the United States. J Urol. 2014 Dec; 192(6):1650-6. View in: Pubmed\n\nAdrenocortical carcinoma: the management of metastatic disease. Crit Rev Oncol Hematol. 2014 Nov; 92(2):123-32. View in: Pubmed\n\nCancer-specific outcomes among young adults without health insurance. J Clin Oncol. 2014 Jul 01; 32(19):2025-30. View in: Pubmed\n\nWE-A-17A-03: Catheter Digitization in High-Dose-Rate Brachytherapy with the Assistance of An Electromagnetic (EM) Tracking System. Med Phys. 2014 Jun; 41(6):487-488. View in: Pubmed\n\nACR Appropriateness Criteria® Definitive External-Beam Irradiation in stage T1 and T2 prostate cancer. Am J Clin Oncol. 2014 Jun; 37(3):278-88. View in: Pubmed\n\nThe role of radical prostatectomy and lymph node dissection in the treatment of young men with high-grade node-positive prostate cancer: less is more--the benefits of surgery do not yet outweigh potential harms. Oncology (Williston Park). 2014 Jun; 28(6):523, 525. View in: Pubmed\n\nUse of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term results. Brachytherapy. 2014 Sep-Oct; 13(5):442-9. View in: Pubmed\n\nResponse to Drs Rogers, Hayes, and Demanes. Brachytherapy. 2014 Sep-Oct; 13(5):523-5. View in: Pubmed\n\nRacial disparities in an aging population: the relationship between age and race in the management of African American men with high-risk prostate cancer. J Geriatr Oncol. 2014 Oct 01; 5(4):352-8. View in: Pubmed\n\nGetting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urol Oncol. 2014 Nov; 32(8):1285-91. View in: Pubmed\n\nRacial disparities in prostate cancer-specific mortality in men with low-risk prostate cancer. Clin Genitourin Cancer. 2014 Oct; 12(5):e189-95. View in: Pubmed\n\nRefusal of curative radiation therapy and surgery among patients with cancer. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):756-64. View in: Pubmed\n\nHydrogel Spacing for Radiotherapy of Prostate Cancer: A Review of the Literature. Urol Pract. 2014 Jul; 1(2):79-85. View in: Pubmed\n\nComparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. J Clin Oncol. 2014 May 10; 32(14):1419-26. View in: Pubmed\n\nWeight gain on androgen deprivation therapy: which patients are at highest risk? Urology. 2014 Jun; 83(6):1316-21. View in: Pubmed\n\nPerceptions of radiation oncologists and urologists on sources and type of evidence to inform prostate cancer treatment decisions. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):277-83. View in: Pubmed\n\nDisparities in selective referral for cancer surgeries: implications for the current healthcare delivery system. BMJ Open. 2014 Mar 23; 4(3):e003921. View in: Pubmed\n\nPlacement of empty catheters for an HDR-emulating LDR prostate brachytherapy technique: comparison to standard intraoperative planning. Brachytherapy. 2014 Jul-Aug; 13(4):375-9. View in: Pubmed\n\nPopulation-based comparative effectiveness of salvage radical prostatectomy vs cryotherapy. Urology. 2014 Mar; 83(3):653-7. View in: Pubmed\n\nSpecialty bias in treatment recommendations and quality of life among radiation oncologists and urologists for localized prostate cancer. Prostate Cancer Prostatic Dis. 2014 Jun; 17(2):163-9. View in: Pubmed\n\nLack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer. 2014 May 15; 120(10):1532-9. View in: Pubmed\n\nIntensity-modulated radiation therapy leads to survival benefit only in patients with high-risk prostate cancer: a population-based study. Ann Oncol. 2014 May; 25(5):979-86. View in: Pubmed\n\nNatural history of untreated prostate specific antigen radiorecurrent prostate cancer in men with favorable prognostic indicators. Prostate Cancer. 2014; 2014:912943. View in: Pubmed\n\nComparative effectiveness of robot-assisted versus open radical prostatectomy cancer control. Eur Urol. 2014 Oct; 66(4):666-72. View in: Pubmed\n\nCytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC). BJU Int. 2014 May; 113(5b):E67-74. View in: Pubmed\n\nGonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol. 2014 Dec; 66(6):1125-32. View in: Pubmed\n\nTestosterone replacement therapy following the diagnosis of prostate cancer: outcomes and utilization trends. J Sex Med. 2014 Apr; 11(4):1063-1070. View in: Pubmed\n\nA national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer. BJU Int. 2014 May; 113(5b):E106-11. View in: Pubmed\n\nPopulation-based determinants of radical prostatectomy operative time. BJU Int. 2014 May; 113(5b):E112-8. View in: Pubmed\n\nMedical oncology consultation and minimization of overtreatment in men with low-risk prostate cancer. J Oncol Pract. 2014 Mar; 10(2):107-12. View in: Pubmed\n\nCryptochrome-mediated light responses in plants. Enzymes. 2014; 35:167-89. View in: Pubmed\n\nThe health care burden of skeletal related events in patients with renal cell carcinoma and bone metastasis. J Urol. 2014 Jun; 191(6):1678-84. View in: Pubmed\n\nACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer. Brachytherapy. 2014 Jan-Feb; 13(1):27-31. View in: Pubmed\n\nOptimal timing of early versus delayed adjuvant radiotherapy following radical prostatectomy for locally advanced prostate cancer. Urol Oncol. 2014 Apr; 32(3):303-8. View in: Pubmed\n\nImpact of national guidelines on brachytherapy monotherapy practice patterns for prostate cancer. Cancer. 2014 Mar 15; 120(6):824-32. View in: Pubmed\n\nModels of care and NCCN guideline adherence in very-low-risk prostate cancer. J Natl Compr Canc Netw. 2013 Nov; 11(11):1364-72. View in: Pubmed\n\nNovel use of a hydrogel spacer permits reirradiation in otherwise incurable recurrent gynecologic cancers. J Clin Oncol. 2013 Dec 01; 31(34):e446-7. View in: Pubmed\n\nUnderutilization of radiation therapy in patients with glioblastoma: predictive factors and outcomes. Cancer. 2014 Jan 15; 120(2):238-43. View in: Pubmed\n\nPSA screening: the case in favor. Oncology (Williston Park). 2013 Oct; 27(10):980, 982. View in: Pubmed\n\nCancer control and complications of salvage local therapy after failure of radiotherapy for prostate cancer: a systematic review. Semin Radiat Oncol. 2013 Jul; 23(3):222-34. View in: Pubmed\n\nThe role of focal therapy in the management of localised prostate cancer: a systematic review. Eur Urol. 2014 Oct; 66(4):732-51. View in: Pubmed\n\nRisk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors. Br J Cancer. 2013 Jun 25; 108(12):2478-84. View in: Pubmed\n\nCardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. Eur Heart J. 2014 Mar; 35(10):612-23. View in: Pubmed\n\nIncidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors. Ann Oncol. 2013 Aug; 24(8):2092-7. View in: Pubmed\n\nIdentification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer. Brachytherapy. 2013 Sep-Oct; 12(5):415-21. View in: Pubmed\n\nOutcomes in stage I testicular seminoma: a population-based study of 9193 patients. Cancer. 2013 Aug 01; 119(15):2771-7. View in: Pubmed\n\nPatterns of care and outcomes of radiotherapy for lymph node positivity after radical prostatectomy. BJU Int. 2013 Jun; 111(8):1208-14. View in: Pubmed\n\nAndrogen-deprivation therapy and cardiovascular harm: let's not throw out the baby with the bathwater. Eur Urol. 2014 Apr; 65(4):710-2. View in: Pubmed\n\nComparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007. BJU Int. 2013 Aug; 112(4):E273-80. View in: Pubmed\n\nOvertreatment of low-risk prostate cancer in the United States: Incidence, cost, complications, and implications for the screening debate. J Clin Oncol. 2013 Feb 20; 31(6_suppl):161. View in: Pubmed\n\nAssociations between single nucleotide polymorphisms (SNPs) in inflammation-related genes and quality of life after radiation therapy (RT) for prostate cancer. J Clin Oncol. 2013 Feb 20; 31(6_suppl):2. View in: Pubmed\n\nMultidisciplinary care and management of very low-risk prostate cancer. J Clin Oncol. 2013 Feb 20; 31(6_suppl):55. View in: Pubmed\n\nIncidence and risk of infections in renal cell cancer (RCC) and non-RCC patients treated with everolimus and temsirolimus: A meta-analysis of randomized control trials. J Clin Oncol. 2013 Feb 20; 31(6_suppl):353. View in: Pubmed\n\nDosimetic quality and evolution of edema after prostate brachytherapy for small prostates: Implications for the use of newer isotopes. J Clin Oncol. 2013 Feb 20; 31(6_suppl):232. View in: Pubmed\n\nIncidence and risk of treatment-related mortality in patients with renal cell cancer (RCC) and non-RCC treated with mammalian target of rapamycin (mTOR) inhibitors. J Clin Oncol. 2013 Feb 20; 31(6_suppl):347. View in: Pubmed\n\nLocation of local recurrence after MRI-guided partial prostate brachytherapy targeting only the peripheral zone: Implications for focal therapy. J Clin Oncol. 2013 Feb 20; 31(6_suppl):149. View in: Pubmed\n\nAge, comorbidity, and the risk of death in men with PSA failure following radiation therapy. J Clin Oncol. 2013 Feb 20; 31(6_suppl):82. View in: Pubmed\n\nA single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer. Clin Cancer Res. 2013 Mar 15; 19(6):1612-9. View in: Pubmed\n\nACR Appropriateness Criteria prostate cancer--pretreatment detection, staging, and surveillance. J Am Coll Radiol. 2013 Feb; 10(2):83-92. View in: Pubmed\n\nReduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology. 2013 Jan; 81(1):130-4. View in: Pubmed\n\nAndrogen deprivation for prostate cancer: when and how, the good and the bad. Am Soc Clin Oncol Educ Book. 2013. View in: Pubmed\n\nClinical implementation of quality of life instruments and prediction tools for localized prostate cancer: results from a national survey of radiation oncologists and urologists. J Urol. 2013 Jun; 189(6):2092-8. View in: Pubmed\n\nCertificate of need programs, intensity modulated radiation therapy use and the cost of prostate cancer care. J Urol. 2013 Jan; 189(1):75-9. View in: Pubmed\n\nHarms versus benefits with duration of androgen suppression. Lancet Oncol. 2012 Dec; 13(12):1182-3. View in: Pubmed\n\nInfluence of surgeon and hospital volume on radical prostatectomy costs. J Urol. 2012 Dec; 188(6):2198-202. View in: Pubmed\n\nMicroinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy. Ann Surg Oncol. 2013 Mar; 20(3):811-8. View in: Pubmed\n\nUpdated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy. J Urol. 2012 Oct; 188(4):1151-6. View in: Pubmed\n\nMultidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012 Sep 01; 30(25):3071-6. View in: Pubmed\n\nMorbidity and costs of salvage vs. primary radical prostatectomy in older men. Urol Oncol. 2013 Nov; 31(8):1477-82. View in: Pubmed\n\nBiopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockade. BJU Int. 2012 Nov; 110(9):1252-6. View in: Pubmed\n\nHigh-dose-rate brachytherapy for prostate cancer in a previously radiated patient with polyethylene glycol hydrogel spacing to reduce rectal dose: case report and review of the literature. Brachytherapy. 2013 Jan-Feb; 12(1):77-83. View in: Pubmed\n\nPatient-reported quality of life during radiation treatment for localized prostate cancer: results from a prospective phase II trial. BJU Int. 2012 Dec; 110(11):1690-5. View in: Pubmed\n\nPosttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality. J Urol. 2012 Jun; 187(6):2068-73. View in: Pubmed\n\nComparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. Eur Urol. 2012 Jun; 61(6):1239-44. View in: Pubmed\n\nHospital volume, utilization, costs and outcomes of robot-assisted laparoscopic radical prostatectomy. J Urol. 2012 May; 187(5):1632-7. View in: Pubmed\n\nAddition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer. Ann Oncol. 2012 Sep; 23(9):2346-2352. View in: Pubmed\n\nBarriers to the implementation of surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys. 2012 Oct 01; 84(2):383-9. View in: Pubmed\n\nIncidence of reduced penis size among men with recurrent prostate cancer previously treated with surgery, radiation plus androgen deprivation, or radiation alone. J Clin Oncol. 2012 Feb 10; 30(5_suppl):38. View in: Pubmed\n\nMultidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012 Feb 10; 30(5_suppl):131. View in: Pubmed\n\nImpact of race on prostate cancer selection and cause-specific mortality: A SEER database analysis. J Clin Oncol. 2012 Feb 10; 30(5_suppl):248. View in: Pubmed\n\nVariability in prostate volume as determined by MRI versus ultrasound and its impact on treatment recommendations for patients with favorable-risk prostate cancer. J Clin Oncol. 2012 Feb 10; 30(5_suppl):249. View in: Pubmed\n\nEffect of adding short-term androgen deprivation therapy to dose-escalated radiation therapy on failure-free survival for select men with intermediate-risk prostate cancer. J Clin Oncol. 2012 Feb 10; 30(5_suppl):176. View in: Pubmed\n\nLong-term results of MRI-guided partial prostate brachytherapy for favorable-risk prostate cancer: Implications for focal therapy. J Clin Oncol. 2012 Feb 10; 30(5_suppl):114. View in: Pubmed\n\nAndrogen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol. 2012 Jun; 61(6):1119-28. View in: Pubmed\n\nTwo solutions for registration of ultrasound to MRI for image-guided prostate interventions. Annu Int Conf IEEE Eng Med Biol Soc. 2012; 2012:1129-32. View in: Pubmed\n\nComparative effectiveness of cryotherapy vs brachytherapy for localised prostate cancer. BJU Int. 2012 Jul; 110(2 Pt 2):E92-8. View in: Pubmed\n\nAssociation of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011 Dec 07; 306(21):2359-66. View in: Pubmed\n\nHormonal therapy or external-beam radiation with brachytherapy and the risk of death from prostate cancer in men with intermediate risk prostate cancer. Clin Genitourin Cancer. 2012 Mar; 10(1):21-5. View in: Pubmed\n\nCardiovascular comorbidity and treatment regret in men with recurrent prostate cancer. BJU Int. 2012 Jul; 110(2):201-5. View in: Pubmed\n\nLow rate of clinician-scored gynecomastia induced by 6 months of combined androgen blockade in a randomized trial: Implications for prophylactic breast irradiation. Pract Radiat Oncol. 2012 Jul-Sep; 2(3):172-178. View in: Pubmed\n\nAge, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol. 2011 Oct 10; 29(29):3885-91. View in: Pubmed\n\nInappropriate utilization of radiographic imaging in men with newly diagnosed prostate cancer in the United States. Cancer. 2012 Mar 01; 118(5):1260-7. View in: Pubmed\n\nExpanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol. 2011 Sep; 186(3):865-72. View in: Pubmed\n\nInfluence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys. 2012 Mar 15; 82(4):1411-6. View in: Pubmed\n\nBasal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2012 Mar 01; 82(3):1185-91. View in: Pubmed\n\nStepwise approach for nerve sparing without countertraction during robot-assisted radical prostatectomy: technique and outcomes. Eur Urol. 2011 Sep; 60(3):536-47. View in: Pubmed\n\nThermal ablation vs surgery for localized kidney cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis. Urology. 2011 Jul; 78(1):93-8. View in: Pubmed\n\nOveruse of imaging for staging low risk prostate cancer. J Urol. 2011 May; 185(5):1645-9. View in: Pubmed\n\nCost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol. 2011 Apr 20; 29(12):1517-24. View in: Pubmed\n\nUtilization and expense of adjuvant cancer therapies following radical prostatectomy. Cancer. 2011 Nov 01; 117(21):4846-54. View in: Pubmed\n\nLinear accelerator-based stereotactic radiosurgery for brainstem metastases: the Dana-Farber/Brigham and Women's Cancer Center experience. J Neurooncol. 2011 Sep; 104(2):553-7. View in: Pubmed\n\nCongestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011 Feb 20; 29(6):632-8. View in: Pubmed\n\nThe debate over prostate cancer screening guidelines. Virtual Mentor. 2011 Jan 01; 13(1):10-5. View in: Pubmed\n\nBevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol. 2011 Jun; 22(6):1404-1412. View in: Pubmed\n\nRecommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol. 2011 Jan; 185(1):116-20. View in: Pubmed\n\nInterfractional variations in the setup of pelvic bony anatomy and soft tissue, and their implications on the delivery of proton therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Jul 01; 80(3):928-37. View in: Pubmed\n\nCoronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation. Cancer. 2011 Jan 15; 117(2):406-13. View in: Pubmed\n\nDeterminants of performing radical prostatectomy pelvic lymph node dissection and the number of lymph nodes removed in elderly men. Urology. 2011 Feb; 77(2):402-6. View in: Pubmed\n\nWhich patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy. Urology. 2010 Nov; 76(5):1201-5. View in: Pubmed\n\nFatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J Clin Oncol. 2010 Sep 01; 28(25):3958-64. View in: Pubmed\n\nDeciding which patients to treat with salvage radiotherapy after prostatectomy. Oncology (Williston Park). 2010 Jul; 24(8):705, 711. View in: Pubmed\n\nRisk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size. Int J Radiat Oncol Biol Phys. 2011 Apr 01; 79(5):1318-22. View in: Pubmed\n\nImpact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer. 2010 Apr 15; 116(8):1887-92. View in: Pubmed\n\nFatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 2010 Apr; 6(4):551-62. View in: Pubmed\n\nProstate cancer screening in men 75 years old or older: an assessment of self-reported health status and life expectancy. J Urol. 2010 May; 183(5):1798-802. View in: Pubmed\n\nThe 'CaP Calculator': an online decision support tool for clinically localized prostate cancer. BJU Int. 2010 May; 105(10):1417-22. View in: Pubmed\n\nRectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial. Int J Radiat Oncol Biol Phys. 2010 Nov 15; 78(4):1081-5. View in: Pubmed\n\nThe association between biological subtype and isolated regional nodal failure after breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2010 May 01; 77(1):188-96. View in: Pubmed\n\nComorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence. Cancer. 2010 Feb 01; 116(3):610-5. View in: Pubmed\n\nEditorial comment. J Urol. 2010 Mar; 183(3):989. View in: Pubmed\n\nRadiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group. Int J Radiat Oncol Biol Phys. 2010 Jul 15; 77(4):1046-52. View in: Pubmed\n\nEvaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence. J Clin Oncol. 2009 Dec 10; 27(35):6000-5. View in: Pubmed\n\nPostrandomization analysis assessing survival following radiation therapy (RT) with or without 6 months of androgen suppression therapy (AST) for localized prostate cancer (PCa). J Clin Oncol. 2009 May 20; 27(15_suppl):5129. View in: Pubmed\n\nThe impact of Skp2 overexpression on recurrence-free survival following radical prostatectomy. Urol Oncol. 2011 May-Jun; 29(3):302-8. View in: Pubmed\n\nPatient-reported quality of life after salvage brachytherapy for radio-recurrent prostate cancer: A prospective Phase II study. Brachytherapy. 2009 Oct-Dec; 8(4):345-52. View in: Pubmed\n\nSurvival following radiation and androgen suppression therapy for prostate cancer in healthy older men: implications for screening recommendations. Int J Radiat Oncol Biol Phys. 2010 Feb 01; 76(2):337-41. View in: Pubmed\n\nPredicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. Int J Radiat Oncol Biol Phys. 2009 May 01; 74(1):104-9. View in: Pubmed\n\nBiochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer : implications for management. Cancer. 2008 Dec 01; 113(11):3146-52. View in: Pubmed\n\nOverexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab Invest. 2008 Dec; 88(12):1340-8. View in: Pubmed\n\nPrediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 2008 Nov; 9(11):1039-47. View in: Pubmed\n\nPredicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int J Radiat Oncol Biol Phys. 2009 Mar 01; 73(3):659-64. View in: Pubmed\n\nProton-beam vs intensity-modulated radiation therapy. Which is best for treating prostate cancer? Oncology (Williston Park). 2008 Jun; 22(7):748-54; discussion 754, 757. View in: Pubmed\n\nThe association between overexpression of skp2 and the risk of recurrence following prostatectomy. J Clin Oncol. 2008 May 20; 26(15_suppl):11052. View in: Pubmed\n\nThe pathogenesis of prostate cancer: from molecular to metabolic alterations. Diagn Histopathol (Oxf). 2008 May; 14(5):195-201. View in: Pubmed\n\nTargeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer despite two negative randomized trials. J Clin Oncol. 2008 Apr 20; 26(12):2055-6; author reply 2056-7. View in: Pubmed\n\nBreast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008 May 10; 26(14):2373-8. View in: Pubmed\n\nPatient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer. 2007 Oct 01; 110(7):1417-28. View in: Pubmed\n\nMagnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study. Cancer. 2007 Oct 01; 110(7):1485-92. View in: Pubmed\n\nHigh-dose external beam radiation for localized prostate cancer: current status and future challenges. Cancer J. 2007 Sep-Oct; 13(5):295-301. View in: Pubmed\n\nEffect of definition of preradiotherapy prostate-specific antigen velocity on its association with prostate cancer-specific mortality and all-cause mortality. Urology. 2007 Aug; 70(2):288-93. View in: Pubmed\n\nRadiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys. 2007 Oct 01; 69(2):444-53. View in: Pubmed\n\nA placebo-controlled trial of etanercept, a tumor necrosis factor (TNF) inhibitor, in patients with the cancer anorexia/weight loss syndrome. North Central Cancer Treatment Group (NCCTG) trial N00C1. J Clin Oncol. 2006 Jun 20; 24(18_suppl):8534. View in: Pubmed\n\nThe impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate carcinoma. Cancer. 2005 May 15; 103(10):2053-9. View in: Pubmed\n\nResults of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol. 2005 Mar 01; 23(7):1507-13. View in: Pubmed\n\nThe effect of excessive anticoagulation on mortality and morbidity in hospitalized patients with anticoagulant-related major hemorrhage. Arch Intern Med. 2004 Jul 26; 164(14):1557-60. View in: Pubmed\n\nThe impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):4503. View in: Pubmed\n\nThe impact of pathology review on treatment recommendations for patients with adenocarcinoma of the prostate. Urol Oncol. 2004 Jul-Aug; 22(4):295-9. View in: Pubmed\n\nQuantifying the impact of seminal vesicle invasion identified using endorectal magnetic resonance imaging on PSA outcome after radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004 Jun 01; 59(2):400-5. View in: Pubmed\n\nIncreased lymphoblast-like cells following umbilical cord blood stem cell transplantation do not predict recurrent acute leukemia. Leukemia. 2002 Oct; 16(10):2171-2. View in: Pubmed\n\nFas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis. Exp Hematol. 1999 Oct; 27(10):1519-27. View in: Pubmed\n\nCan pathology residents be trained to perform adequate bone marrow biopsies? Acad Med. 1999 Apr; 74(4):452. View in: Pubmed"
    }
}